METABOLIC IMPACT OF CARDIAC HORMON THERAPY
Gender dysphoria (DG) implies a discordance between the gender assigned at birth and the self-perceived one. Male transgender or male transsexual (FTM) are identified with the male gender and have been assigned as female at birth. Transgender women or transsexual women (MTF) are identified as women but have been assigned as men at birth. There are those who do not seek extreme masculinization or feminization, which allows the term "sexual diversity" to cover these cases.
- Wierckx K, Elaut E, Declercq E, Heylens G, De Cuypere G, Taes Y, Kaufman J, Sjoen G. Prevalence of cardiovascular disease and cancer during cross-sex hormone therapy in a large cohort of trans persons: a case-control study. EJE 2013; 169:471-8.
- Maraka S, Singh N, Rodríguez-Gutiérrez R, Davidge-Pitts C, Nippoldt T, Prokop L, Murad H. Sex steroid and cardiovascular outcomes in transgender individuals: a systematic review and meta-analysis. JCEM Nov 2017; Vol 102, Issue 11. Doi: 10.1210/jc.2017-01643.
- Velho I, Fighera T, Zeigelmann P, Spritzer P. Effects of testosterone therapy on BMI, blood presure, and laboratory profile of transgender men: a systematic review. Andrology 2017 Sep; 5(5):881-888. Doi: 10.1111/andr.12382.
- Nota NM, et al. Ocurrence of acute cardiovascular events in transgender individuals receiving hormonal therapy. Circulation 2019; 139(11):1461-1462.
Copyright (c) 2020 Sociedad Argentina de Diabetes Asociación Civil